The last year has demonstrated that a sound financing strategy and compelling company narrative are essential to securing funding – it’s become more important than ever that investors are excited before taking the plunge. Given the current economic environment that is causing challenges in biopharma, how should companies be approaching funding in 2024?

Listen to this discussion on different kinds of funding options available, how companies can optimize their chances to secure funding and how they should be assessing VCs in addition to alternative partners – particularly if your company will be seeking funding at JPM next week. Our host and guests also discuss current challenges, how to weather adversity, and what investment trends are anticipated for next year.

You can also watch the roundtable on BioSpace.

Host

⁠⁠⁠⁠⁠⁠Lori Ellis⁠⁠⁠⁠⁠⁠, Head of Insights, BioSpace

Guests

Jeff Burton, CFO, Halia Therapeutics

Karen Harris, CFO and Head of Mission-Related Investing, The Alzheimer's Drug Foundation

Rob Williamson, President and COO, Triumvira Immunologics

Alternative funding strategies to discuss at JPM with Halia Therapeutics, the ADDF and Triumvira Immunologics

BioSpace

Alternative funding strategies to discuss at JPM with Halia Therapeutics, the ADDF and Triumvira Immunologics